This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA's Management Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Some of those include our lead candidate which is gevokizumab, which is a monoclonal antibody which is an allosteric binder to IL-1 beta, and then some other compounds a little further in the pipeline such as the XMet program which we might discuss a little later also. These are all monoclonal antibodies that bind to allosteric as opposed to orthostatic sites or the non-business end part of the molecule.

The company I think is making a concerted effort to get more value for its assets. So in fact as you are aware, we are developing gevokizumab in conjunction with our partner Servier on a global basis, initially for non-infectious uveitis which is our lead indication and is now in Phase 3 and will be on a worldwide basis. And then for a series of other indications that the development should occur in the next few years and we should get some good data on that product and then hopefully we will have a few other things as we go forward.

Question-and-Answer Session

Yigal Nochomovitz - Morgan Stanley

Got it. It’s a good overview. Maybe we could jump in then on the lead asset, gevokizumab. Give the investors some sense of comparative profile of your IL-1 data agent relative to what else is out there in the world. And I am thinking of things like (inaudible) and so forth.

Paul Rubin

Sure. I think that if you look at all the products that are on the market or in development for modulating IL-1 beta signaling, we are I think unique. We are the only compound, as I mentioned, that binds to a part of IL-1 beta where we can dramatically reduce the signal that occurs from IL-1 beta stimulating its receptors, we still allow interaction of IL-1 beta with its receptor. And what that does it enhances clearance of the molecule and it prevents the existence of circulating antibody like [complexes], which can be detrimental.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs